Molbio Diagnostics launches transformative scale up partnership prog for healthcare innovation
Molbio Diagnostics will select high-potential MedTech startups and SMEs with groundbreaking solutions in rapid POC for high-sensitivity immunodiagnostics and early cancer detection
Molbio Diagnostics has launched ‘EDGE’- an innovative scaleup partnership programme dedicated to accelerating game-changing healthcare technologies. As part of EDGE, Molbio Diagnostics will select high-potential MedTech startups and SMEs with groundbreaking solutions in rapid POC for high-sensitivity immunodiagnostics and early cancer detection.
The main objective of the programme is to help start-ups overcome critical hurdles in product development, translation and scaling up with the assistance of Molbio’s expertise, guidance and support. Participants will be able to leverage Molbio’s extensive network and expertise to bring their innovation to a worldwide audience.
Over 12 weeks, selected participants will receive intensive mentorship, resources and expertise from Molbio’s team of seasoned professionals. This culminates in the opportunity to forge co-development, manufacturing, or global sales partnerships with Molbio. At the end of the programme, Molbio will engage with a few cohort participants for future partnerships which will involve bridge funding for product co-development, licensing, sales and distribution. The programme will be conducted in hybrid mode and each cohort participant will receive bespoke guidance.
With the launch of EDGE, Molbio is set to reinforce its commitment to providing equitable & accessible healthcare by delivering solutions that truly matter.
To register for the program log on to https://partnership.bigteclabs.com/edge/.The last date to register is March 15, 2024.
